EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0

作者：

Gordon, Kenneth B. ^{[1
]}

Strober, Bruce ^{[2
,3
]}

Lebwohl, Mark ^{[4
]}

Augustin, Matthias ^{[5
]}

Blauvelt, Andrew ^{[6
]}

Poulin, Yves ^{[7
]}

Papp, Kim A. ^{[8
,9
]}

Sofen, Howard ^{[10
]}

Puig, Lluis ^{[11
]}

Foley, Peter ^{[12
,13
,14
]}

Ohtsuki, Mamitaro ^{[15
]}

Flack, Mary ^{[16
]}

Geng, Ziqian ^{[17
]}

Gu, Yihua ^{[17
]}

Valdes, Joaquin M. ^{[17
]}

Thompson, Elizabeth H. Z. ^{[18
]}

Bachelez, Herve ^{[19
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] Univ Connecticut, Ctr Hlth, Farmington, CT USA

[3] Prob Med Res, Farmington, CT USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Univ Med Ctr Hamburg Eppendorf UKE, Hamburg, Germany

[6] Oregon Med Res Ctr, Portland, OR USA

[7] Ctr Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[8] K Papp Clin Res, Waterloo, ON, Canada

[9] Prob Med Res, Waterloo, ON, Canada

[10] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[11] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

[12] Univ Melbourne, Parkville, Vic, Australia

[13] Skin & Canc Fdn Inc, Carlton, Vic, Australia

[14] Prob Med Res, Carlton, Vic, Australia

[15] Jichi Med Univ, Shimotsuke, Japan

[16] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[17] AbbVie Inc, N Chicago, IL USA

[18] AbbVie Inc, Redwood City, CA USA

[19] Univ Paris Diderot, Sorbonne Paris Cite, St Louis Hosp, Paris, France

来源：

ACTA DERMATO-VENEREOLOGICA | 2018年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P062

引用

页码：28 / 29

页数：2

共 50 条

[1] Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Gordon, Kenneth B.
Strober, Bruce
Lebwohl, Mark
Augustin, Matthias
Blauvelt, Andrew
Poulin, Yves
Papp, Kim A.
Sofen, Howard
Puig, Lluis
Foley, Peter
Ohtsuki, Mamitaro
Flack, Mary
Geng, Ziqian
Gu, Yihua
Valdes, Joaquin M.
Thompson, Elizabeth H. Z.
Bachelez, Herve
LANCET, 2018, 392 (10148): : 650 - 661
[2] Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
Cai, L.
Gu, J.
Zheng, J.
Zheng, M.
Wang, G.
Xi, L. -Y.
Hao, F.
Liu, X. -M.
Sun, Q. -N.
Wang, Y.
Lai, W.
Fang, H.
Tu, Y. -T.
Sun, Q.
Chen, J.
Gao, X. -H.
Gu, Y.
Teixeira, H. D.
Zhang, J. -Z.
Okun, M. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 89 - 95
[3] Efficacy and safety of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: Results from the phase 3, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial
Reich, Kristian
Armstrong, April W.
Foley, Peter
Song, Michael
Wasfi, Yasmine
Randazzo, Bruce
Shen, Yaung-Kaung
Gordon, Kenneth B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB111 - AB111
[4] Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: Integrated analysis of two phase 3 trials
Foley, Peter
Strober, Bruce
Valdecantos, Wendell C.
Photowala, Huzefa
Zhan, Tianyu
Menter, Alan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB49 - AB49
[5] Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind Study
Zhang, Jianzhong
Gu, Jun
Zheng, Jie
Zheng, Min
Wang, Gang
Gu, Yihua
Okun, Martin
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB232 - AB232
[6] Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
Merola, Joseph F.
Parish, Lawrence Charles
Guenther, Lyn
Lynde, Charles
Lacour, Jean -Philippe
Staubach, Petra
Cheng, Sue
Paris, Maria
Picard, Hernan
Deignan, Cynthia
Jardon, Shauna
Chen, Mindy
Papp, Kim A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 485 - 493
[7] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
Reich, K.
Gooderham, M.
Thaci, D.
Crowley, J. J.
Ryan, C.
Kruger, J. G.
Tsai, T.
Flack, M.
Gu, Y.
Williams, D. A.
Thompson, E. H.
Paul, C.
EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
[8] Efficacy and safety of risankizumab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results from the 28-week randomized, double-blind period of an ongoing phase 3 study in Brazil
Cestari, Tania F.
Souza, Cacilda daSilva
Azulay-Abulafia, Luna
Romiti, Ricardo
Carvalho, Andre V. E.
Silva de Castro, Caio Cesar
Marques, Silvio Alencar
Antonio, Joao Roberto
Fabricio, Lincoln
Kalabic, Jasmina
Oyafuso, Luiza Keiko
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB88 - AB88
[9] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
Blauvelt, Andrew
Papp, Kim A.
Gooderham, Melinda
Langley, Richard G.
Leonardi, Craig
Lacour, Jean-Philippe
Philipp, Sandra
Tyring, Stephen
Bukhalo, Michael
Wu, Jashin J.
Bagel, Jerry
Frankel, Ellen H.
Pariser, David
Flack, Mary
Scherer, Joseph
Geng, Ziqian
Gu, Yihua
Camez, Anne
Thompson, Elizabeth H. Z.
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
[10] Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent Trial
Reich, Kristian
Gooderham, Melinda
Thaci, Diamant
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB52 - AB52

← 1 2 3 4 5 →